Anagrelide: A novel agent for the treatment of myeloproliferative disorders

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 3, 2000, Pages 537-546

  Pescatore, Scott L ^a   Lindley, Celeste ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Anagrelide; Dose; Mechanism of action; Myeloproliferative disorders; Pharmacokinetics; Toxicity

Indexed keywords

ANAGRELIDE; FIBRINOLYTIC AGENT; QUINAZOLINE DERIVATIVE;

CLINICAL TRIAL; DRUG APPROVAL; ECONOMICS; FOOD AND DRUG ADMINISTRATION; HUMAN; MYELOPROLIFERATIVE DISORDER; REVIEW; UNITED STATES;

CLINICAL TRIALS; DRUG APPROVAL; FIBRINOLYTIC AGENTS; HUMANS; MYELOPROLIFERATIVE DISORDERS; QUINAZOLINES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0034157369     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.3.537     Document Type: Review

References (28)

1. Anagrelide for essential thrombocythemia. Med. Lett. (1997) 39(1016):120.
2. MICHIELS JJ, JUVONEN E: Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin. Thromb. Hemost. (1997)23:339-347.
3. MICHIELS JJ et al.: Diagnosis, athogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and myelofibrosis. Neth. J. Med. (1999) 54:46-62.
4. GILBERT HS: Historical perspective on the treatment of essential thrombocythemia and polycythemia vera Semin. Hematol. (1999) 36(1):19-22. A historical review of the treatment of ET and PV.
5. TEFFERI A: Introduction: overview of chronic myeloproliferative disorders. Semin. Hematol. (1999) 36(1):1-2.
6. TERRERI A, SILVERSTEIN MN, PETITT RM et al.: Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. Semin. Thromb. Hemost (1997) 23(4)579-382.
7. FRUCHTMAN SM, MACK K, KAPLAN ME et al.: From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Semin. Hematol. (1997) 34(1):17-23. The PVSG report on the use of HU for PV.
8. TEFFERI A, SILVERSTEIN MN, HOAGLAND HC: Primary thrombocythemia. Semin. Oncol. (1995) 4:334-340.
9. BARBUI T, FINAZZI G: Treatment of polycythemia vera. Haematologica (1998) 83:143-149.
10. BALDUINI CL: Primary thrombocythemia: new drugs for an evolving disease. Haematologica (1992) 77:297-301.
11. GAVER RC, DEED G, PITTMAN KA et al.: Disposition of anagrelide, an inhibitor of platelet aggregation. Clin. Pharmacol. Ther. (1981) 29(3):381-386. A description of the metabolism of anagrelide.
12. MILLS AK, TAYLOR KM, WRIGHT SJ et al.: Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythemia Aust. NZ J. Med. (1999) 29:29-35.
13. SEILER S, ARNOLD AJ, GROVE RI et al.: Effects of anagrelide on platelet cAMP levels, cAMP-dependent protein kinase and thrombin-induced Ca fluxes. J. Pharmacol. Exp. Ther. (1987) 243:767-773.
14. SOLBERG LA, TEFFERI A, OLES KJ et al.: The effects of anagrelide on human megakaryocytopoiesis. Br. J. Haematol. (1997) 99:174-180.
15. OERTEL MD: Anagrelide, a selective thrombocytopenic agent. Am. J. Health Syst. Pharm. (1998) 55:1979-1986. A drug evaluation of anagrelide with literature review.
16. BELLUCCI S, LEGRAND C, BOVAL B et al.: Studies of platelet volume, chemistry and function in patients with essential thrombocythemia treated with anagrelide Br. J. Haematol. (1999) 104:886-892.
17. Agrylin package insert. Roberts Pharmaceutical Corp., Eatontown, NJ, USA (1997).
18. MAZUR EM, ROSMARIN AG, SOHL PA et al.: Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood (1992) 79(8):1931-1937.
19. ANAGRELIDE STUDY GROUP: Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am. J. Med. (1992) 92:69-78. A large, multicentre trial.
20. SPENCER CM, BROGDEN RN: Anagrelide: a review of its pharmacodynamics and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythemia. Drugs (1994) 47(6):809-822. A comprehensive evaluation of anagrelide.
21. ANDES WA, NOVECK J, FLEMING JS: Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb. Haemost. (1984) 52(3):325-328.
22. PETITT RM, MURRAY N, SILVERSTEIN MN et al.: Anagrelidc for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin. Hematol. (1997) 34(1):51-54.
23. Red Book. Medical Economics Co. (1999):173.
24. TEFFERI A, INWARDS DJ, HOYER JD: Spontaneous remission of anemia associated with a myelodysplastic syndrome with disease evolution into a mycloproliferative state. Acta Haematologica (1999) 101:50-52.
25. MCCUNE JS, LILES D, LINDLEY C: Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations. Pharmacotherapy (1997) 17(4):822-826. A case report and critique of anagrelide dosing recommendations.
26. SILVERSTEIN MN, PETITT RM, SOLBERG LA et al.: Anagrelide: a new drug for treating thrombocytosis. N. Engl. J. Med. (1988) 318(20):1292-1294.
27. MAZZUCCONI MG, DESANCTIS V, CHISTOLINI A et al.: Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Haematologica (1992) 77:315-317.
28. BALDUINI CL, BERTOLINO G, NORIS P et al.: Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica (1992) 77:40-43.